Pricing Log in Create free account

Aurinia Pharmaceuticals Inc (AUPH) vs Zymeworks Inc. (ZYME)

Aurinia Pharmaceuticals Inc and Zymeworks Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Zymeworks Inc. are of similar size ($2.2B and $2.0B). Zymeworks Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.8×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 21.0% against −69.8%. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs −404.0%) and the higher return on invested capital (43.0% vs 0.00%). Across the 18 metrics below, Aurinia Pharmaceuticals Inc leads on 16 and Zymeworks Inc. on 2.

Valuation

Metric AUPH ZYME Biotechnology median
P/E 6.78 n/m 10.26
P/S 6.72 56.80 9.18
P/B 3.29 26.24 2.05
Price to free cash flow 12.22 n/m 24.81
EV/EBITDA 10.49 n/m 0.65
EV/Sales 5.33 49.52 8.98
Earnings yield 14.74% (6.99%) (34.89%)
Free cash flow yield 8.18% (5.76%) (24.52%)

Profitability

Metric AUPH ZYME Biotechnology median
Gross margin 90.62% (246.66%) 65.16%
Operating margin 44.78% (418.99%) 0.00%
Net margin 97.68% (404.00%) 0.00%
Free cash flow margin 55.02% (324.68%) 0.00%
Return on equity 61.42% (72.31%) (50.12%)
Return on assets 46.45% (37.25%) (45.60%)
Return on invested capital 42.95% 0.00% 0.00%

Growth

Metric AUPH ZYME Biotechnology median
Revenue growth (TTM) 21.04% (69.78%) 6.26%
EPS growth (last fiscal year) 5,075.00% 33.33% 29.88%
Revenue growth, 5-year CAGR 41.38% 22.16% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AUPH ZYME Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 6.12 6.32 4.89
Net debt to EBITDA (2.58) 2.81 1.01

Dividend

Metric AUPH ZYME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AUPH ZYME Biotechnology median
Market cap 2.17b 2.04b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack